Drug intelligence / Profile preview

haemophilus influenzae type a glycoconjugate vaccine

Development stage: Phase 1
Lead developer: InventVacc Biologicals
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Haemophilus influenzae type a glycoconjugate vaccine is a novel glycoconjugate vaccine developed by InventVacc Biologicals Inc. in collaboration with the National Research Council and other partners. It is designed to prevent serious illness caused by *Haemophilus influenzae* serotype a (Hia), particularly in Indigenous children in Canada and Alaska. The vaccine utilizes the CRM197 protein as a carrier to enhance immunogenicity.

Other names: Hia glycoconjugate vaccine

Targets

Hia CPS (Haemophilus influenzae type a capsular polysaccharide)

Beyond the preview

Go deeper on haemophilus influenzae type a glycoconjugate vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on haemophilus influenzae type a glycoconjugate vaccine.

Explore the full profile